Astrazeneca (AZN) Research & Development (2009 - 2026)

Astrazeneca's Research & Development history runs 18 years deep, the most recent figure standing at -$3.5 billion for Q1 2026.

• In Q1 2026, Research & Development fell 10.54% year-over-year to -$3.5 billion; the TTM figure through Mar 2026 stood at -$14.6 billion (down 4.34% YoY), while the FY2025 annual figure was $14.2 billion, up 4.78% from the prior year.
• Research & Development was -$3.5 billion for Q1 2026 at Astrazeneca, up from -$3.9 billion in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$2.1 billion in Q1 2022 to a low of -$4.7 billion in Q4 2024.
• Historically, Research & Development has averaged -$3.1 billion across 5 years, with a median of -$3.0 billion in 2024.
• Biggest YoY gain for Research & Development was 31.91% in 2022; the steepest drop was 606.29% in 2022.
• A 5-year view of Research & Development shows it stood at -$2.6 billion in 2022, then slipped by 17.07% to -$3.1 billion in 2023, then plunged by 52.2% to -$4.7 billion in 2024, then climbed by 17.43% to -$3.9 billion in 2025, then climbed by 9.58% to -$3.5 billion in 2026.
• The last three Research & Development figures came in at -$3.5 billion (Q1 2026), -$3.9 billion (Q4 2025), and -$3.7 billion (Q3 2025), per Business Quant data.